Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1995-2-2
|
pubmed:abstractText |
We have recently demonstrated that recombinant human interleukin-2 (IL-2) can be successfully encapsulated in small (mean size, 65 nm), unilamellar, long-circulating, sterically stabilized liposomes (SSL, also known as Stealth liposomes). The present study was undertaken to assess in mice the immunomodulatory and anti-tumor effects of SSL-IL-2 in comparison with soluble, unmodified IL-2 and pegilated IL-2 (PEG-IL-2). The main findings were as follows: (a) SSL-IL-2 was significantly more effective than IL-2 in increasing leukocyte number in the blood and spleen (p < 0.05) and triggering spleen lymphokine-activated killer cell activity (p < 0.01; t test). (b) In mice with advanced metastatic carcinoma previously treated with chemotherapy (cyclophosphamide), the survival was two to six times greater following administration of SSL-IL-2 as compared with IL-2 (p < 0.05; log-rank test). Moreover, successful treatment with SSL-IL-2 required lower cumulative doses (1.25 x 10(5) vs. 2.5 x 10(5) CU) and fewer (two versus five) administrations. (c) PEG-IL-2 was a more potent immunostimulator than SSL-IL-2 in normal mice and as effective therapeutically as SSL-IL-2 in tumor-bearing mice. The former agent, however, often caused marked toxicity (up to 40% mortality in some experiments), including severe thrombocytopenia. These findings suggest that SSL-IL-2 is an immunopotentiating agent superior to IL-2 in both normal mice and in tumor-bearing mice pretreated with chemotherapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Liposomes,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/interleukin-2, polyethylene...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1067-5582
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
115-24
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7804526-Adjuvants, Immunologic,
pubmed-meshheading:7804526-Animals,
pubmed-meshheading:7804526-Cell Line,
pubmed-meshheading:7804526-Combined Modality Therapy,
pubmed-meshheading:7804526-Cyclophosphamide,
pubmed-meshheading:7804526-Drug Carriers,
pubmed-meshheading:7804526-Female,
pubmed-meshheading:7804526-Interleukin-2,
pubmed-meshheading:7804526-Liposomes,
pubmed-meshheading:7804526-Mice,
pubmed-meshheading:7804526-Mice, Inbred BALB C,
pubmed-meshheading:7804526-Mice, Inbred C57BL,
pubmed-meshheading:7804526-Neoplasms, Experimental,
pubmed-meshheading:7804526-Polyethylene Glycols
|
pubmed:year |
1994
|
pubmed:articleTitle |
Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice.
|
pubmed:affiliation |
Lautenberg Center for General and Tumor Immunology, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|